Skip to main content

Anavex Life Sciences Corp.

AVXL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001314052

No open-market purchases or sales by Anavex Life Sciences Corp. insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $95.8M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Anavex Life Sciences Corp. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of AVXL: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders150148−2
Shares24.9M24.4M−542.2K (−2.2%)
Value$249.4M$251.4M+$2.01M (+0.8%)

New holders (16)

Institutions that held Anavex Life Sciences Corp. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to AVXL in Q3 2022
InstitutionSharesValue% of portfolio
Occudo Quantitative Strategies LP86,158$889.0K0.07%
Balyasny Asset Management LLC57,097$589.0K0.00%
Prudential Financial Inc37,980$391.0K0.00%
Squarepoint Ops LLC20,068$207.0K0.00%
Advisory Research Inc15,340$158.0K0.02%
Los Angeles Capital Management LLC14,599$151.0K0.00%
Money Concepts Capital Corp13,414$138.0K0.01%
Liberty One Investment Management, LLC13,414$138.0K0.02%
Janney Montgomery Scott LLC10,461$108.0K0.00%
Bridgefront Capital, LLC10,214$105.0K0.11%
Aquatic Capital Management LLC8,700$90.0K0.01%
Point72 Hong Kong Ltd771$8.00K0.00%
China Universal Asset Management Co., Ltd.730$8.00K0.00%
Belvedere Trading LLC582$7.00K0.01%
Wipfli Financial Advisors LLC,137$1.00K0.00%
Lindbrook Capital, LLC39$00.00%

Sold out (18)

Institutions that held Anavex Life Sciences Corp. at the end of Q2 2022 and filed for Q3 2022 without it.